Teplizumab Continues to Show Promise in Slowing Type 1 Diabetes Progression

New research confirms that teplizumab helps preserve insulin-producing cells in people with stage 2 type 1 diabetes, delaying the progression to stage 3. The medication works by reducing the body's attack on these critical cells.

News report, corroborated with 2 indexed studies

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

cure researchbeta cellsadvancements

Key takeaways

Teplizumab is the first FDA-approved drug designed to delay the onset of stage 3 type 1 diabetes in children age 8 and older and adults with stage 2 disease
Clinical trials show that teplizumab preserves insulin production, with patients maintaining better beta-cell function up to 2 years after treatment
Patients treated with teplizumab needed less insulin overall, with reductions averaging 0.08 to 0.10 units per kilogram of body weight per day
Common side effects like rash, headache, and temporary lymphopenia (low white blood cell counts) mostly occur in the first few weeks and generally resolve without intervention
Not everyone responds the same way—some patients progress more slowly and maintain better insulin secretion than others, suggesting individual differences matter

What Is Teplizumab and How Does It Work?

Teplizumab is a monoclonal antibody—a lab-made immune protein—that targets a specific process in type 1 diabetes. In type 1 diabetes, the immune system mistakenly attacks beta cells in the pancreas, which produce insulin. Teplizumab works by quieting this immune attack, helping preserve the body's own insulin production.

The drug targets stage 2 type 1 diabetes, a period before symptoms appear when autoimmune markers are detectable and beta-cell function is declining but insulin-dependent diabetes has not yet developed. By slowing or delaying this progression to stage 3 (clinical type 1 diabetes), teplizumab gives the pancreas more time to make insulin on its own.

Clinical Trial Evidence: What the Data Shows

An integrated analysis of five clinical trials involving 609 patients examined teplizumab's effect on C-peptide, a marker of how much insulin the body is producing. After one course of teplizumab, patients showed an average increase of 0.08 nmol/L in stimulated C-peptide at one year, and this benefit grew to 0.12 nmol/L at two years. These improvements were statistically significant and consistent across studies.

Patients treated with teplizumab also needed less insulin therapy. At one year, insulin use dropped by 0.08 units per kilogram of body weight per day, and by two years, it fell to 0.10 units per kilogram per day. These reductions reflect the drug's core effect: preserving the beta cells that the body relies on to make its own insulin.

Recent detailed analysis of the TN10 trial revealed important patterns. In placebo-treated patients, insulin secretion declined over 12 months. In contrast, insulin secretion actually rose in teplizumab-treated patients during the same period. However, response varied: some patients (termed 'slow-progressors') maintained good insulin secretion and sensitivity, while others ('rapid-progressors') experienced some metabolic decline despite treatment.

Safety: What to Expect

Safety data from nearly 1,500 patient-years of follow-up show that teplizumab is generally well-tolerated. The most common side effects include lymphopenia (temporary reduction in certain white blood cells), rash, and headache.

Importantly, most adverse events occur during and shortly after the first few weeks of treatment and resolve without intervention. This means side effects are typically temporary and do not require additional treatment. This safety profile has been consistent across multiple large clinical trials, providing reassurance for patients and families considering teplizumab.

What This Means for People with Stage 2 Type 1 Diabetes

Teplizumab represents a shift in how type 1 diabetes is managed. Rather than waiting for full disease to develop and then managing insulin with injections or pumps, teplizumab offers an opportunity to intervene earlier—during stage 2—to slow the underlying immune attack. This can delay the point at which a person needs insulin therapy.

It is important to understand that teplizumab does not cure type 1 diabetes and does not stop the disease entirely. Rather, it delays progression from stage 2 to stage 3 and helps preserve some insulin production capacity. The degree of benefit varies between individuals, and ongoing research continues to identify which patients respond best.

For families and individuals navigating the early stages of type 1 diabetes, teplizumab offers a disease-modifying option backed by rigorous clinical trial evidence. Discussions with a healthcare provider can help determine whether teplizumab is appropriate in individual circumstances.

Evidence label

Origin: Endocrinology Advisor (News report). Evidence: News report, corroborated with 2 indexed studies. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.